Format

Send to

Choose Destination
Clin Pharmacol Ther. 2016 Dec;100(6):647-653. doi: 10.1002/cpt.504. Epub 2016 Oct 22.

Leveraging Industry-Academia Collaborations in Adaptive Biomedical Innovation.

Author information

1
Center for Biomedical Innovation, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
2
Technology Licensing Office, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
3
Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
4
Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
5
Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
6
Sanofi, Cambridge, Massachusetts, USA.

Abstract

Despite the rapid pace of biomedical innovation, research and development (R&D) productivity in the pharmaceutical industry has not improved broadly. Increasingly, firms need to leverage new approaches to product development and commercial execution, while maintaining adaptability to rapid changes in the marketplace and in biomedical science. Firms are also seeking ways to capture some of the talent, infrastructure, and innovation that depends on federal R&D investment. As a result, a major transition to external innovation is taking place across the industry. One example of these external innovation initiatives is the Sanofi-MIT Partnership, which provided seed funding to MIT investigators to develop novel solutions and approaches in areas of interest to Sanofi. These projects were highly collaborative, with information and materials flowing both ways. The relatively small amount of funding and short time frame of the awards built an adaptable and flexible process to advance translational science.

PMID:
27617845
DOI:
10.1002/cpt.504
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center